


PRODUCT INFORMATION



ABT-263-d₈
Item No. 34694

CAS Registry No.: 1217620-38-6
Formal Name: 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[[(1R)-3-(4-morpholinyl-d₈)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]-benzamide
Synonym: Navitoclax-d₈
MF: C₄₇H₄₇ClD₈F₃N₅O₆S₃
FW: 982.7
Chemical Purity: ≥90% (ABT-263)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₈); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ABT-263-d₈ is intended for use as an internal standard for the quantification of ABT-263 (Item No. 11500) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

ABT-263-d₈ is supplied as a solid. A stock solution may be made by dissolving the ABT-263-d₈ in the solvent of choice, which should be purged with an inert gas. ABT-263-d₈ is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of ABT-263-d₈ in these solvents is approximately 0.5, 25, and 30 mg/ml, respectively.

Description

ABT-263 is an inhibitor of the Bcl-2 family proteins Bcl-2, Bcl-xL, and Bcl-W (K_i s = <1, <0.5, and <1 nM, respectively).¹ It is selective for Bcl-2, Bcl-xL, and Bcl-W over Mcl-1 and A1 (K_i s = 550 and 354 nM, respectively). ABT-263 is cytotoxic in a panel of small cell lung cancer (SCLC), leukemia, and lymphoma cell lines with a mean EC₅₀ value of 1 μM. It induces apoptosis in influenza A-infected retinal pigment epithelial cells (EC₅₀ = 0.08 μM).² ABT-263 (100 mg/kg) induces tumor regression in NCI H146 SCLC and RS4;11 acute lymphocytic leukemia (ALL) mouse xenograft models.^{1,3}

References

1. Tse, C., Shoemaker, A.R., Adickes, J., *et al.* ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. *Cancer Res.* **68**(9), 3421-3428 (2008).
2. Bulanova, D., Ianevski, A., Bugai, A., *et al.* Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins. *Viruses* **9**(10), E271 (2017).
3. Shoemaker, A.R., Mitten, M.J., Adickes, S., *et al.* Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. *Clin. Cancer Res.* **14**(11), 3268-3277 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM